Lenvatinib Long-Term Responses in Refractory Thyroid Cancer: Our Mono-Institutional Real-Life Experience with the Multidisciplinary Approach and Review of Literature | Zendy

Nerina Denaro | Zendy; Adele Latina | Zendy; Flora Cesario | Zendy; Fabio Bramardi | Zendy; Corrado Lauro | Zendy; Giorgio Borretta | Zendy; Marco Merlano | Zendy

Open Access

Lenvatinib Long-Term Responses in Refractory Thyroid Cancer: Our Mono-Institutional Real-Life Experience with the Multidisciplinary Approach and Review of Literature

Author(s) -

Nerina Denaro,

Adele Latina,

Flora Cesario,

Fabio Bramardi,

Corrado Lauro,

Giorgio Borretta,

Marco Merlano

Publication year - 2019

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000501691

Subject(s) - lenvatinib , medicine , cabozantinib , discontinuation , everolimus , adverse effect , refractory (planetary science) , renal cell carcinoma , oncology , thyroid cancer , kidney cancer , cancer , physics , astrobiology

Lenvatinib (LEN) is a multikinase inhibitor with antiangiogenic properties recently approved in radioactive iodine-refractory differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma in combination with everolimus. LEN-treated patients frequently have adverse events (AEs) that generally require such dose modifications, including drug discontinuation. Hypertension, diarrhea, weight loss, proteinuria, fatigue, and palmar-plantar erythrodysesthesia are reported among the most frequent AEs, often leading to discontinuations or dose modifications. This paper reports a case series focusing on the role of the immediate multidisciplinary approach to manage AEs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research